The CARDIO-TTRansform Scintigraphy Sub-study

Study Summary

The purpose of this study is to examine the changes in amyloid myocardial burden in a subset of the population participating in the ION682884-CS2 (NCT04136171) study, up to 150 participants, after treatment with eplontersen or placebo based on scintigraphy scans performed at Week 140 using the Perugini grade score method.

Conditions

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Interventions / Drugs

Scintigraphy scan

View on ClinicalTrials.gov ↗

Sponsor

IONS

Ionis Pharmaceuticals

Antisense Therapeutics

B68/100

Study Details

Enrollment150 participants

Primary Completion—

Lead SponsorIonis Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:17:53.139407+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.